| Zacks Company Profile for ANI Pharmaceuticals, Inc. (ANIP : NSDQ) |
|
|
| |
| • Company Description |
| ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN.
Number of Employees: 601 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $30.86 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 116,818 shares |
| Shares Outstanding: 17.27 (millions) |
| Market Capitalization: $533.02 (millions) |
| Beta: 1.06 |
| 52 Week High: $60.23 |
| 52 Week Low: $22.73 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-4.43% |
4.65% |
| 12 Week |
-17.64% |
-7.44% |
| Year To Date |
-33.03% |
-18.18% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Nikhil Lalwani - President; and Chief Executive Officer
Patrick D. Walsh - Chairman of the Board
Stephen P. Carey - Senior Vice President; Finance and Chief Financia
Muthusamy Shanmugam - Head of Research and Development and Chief Operati
Thomas J. Haughey - Director
|
|
Peer Information
ANI Pharmaceuticals, Inc. (CORR.)
ANI Pharmaceuticals, Inc. (RSPI)
ANI Pharmaceuticals, Inc. (CGXP)
ANI Pharmaceuticals, Inc. (BGEN)
ANI Pharmaceuticals, Inc. (GTBP)
ANI Pharmaceuticals, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00182C103
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/05/22
|
|
Share - Related Items
Shares Outstanding: 17.27
Most Recent Split Date: 7.00 (0.17:1)
Beta: 1.06
Market Capitalization: $533.02 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $0.04 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $0.74 |
Payout Ratio: 0.00 |
| Number of Estimates in the Fiscal Year Consensus: 3.00 |
Change In Payout Ratio: 0.00 |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/05/22 |
|
|
|
| |
